Liraglutide
SAXAPCOS
Novo Nordisk · Phase 3 · Completed · Enrollment 88
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| Liraglutide Pen Injector (Saxenda) | Obesity + T2D | n/r | 1 | n/r | 5.7% at week 32 |
| Placebo liraglutide pen injector | Obesity + T2D | n/r | 1 | n/r | 1.4% at week 32 |